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MINAR IS A NOVEL NOTCH-2 INTERACTING PROTEIN THAT  
 
REGULATES NOTCH-2 ACTIVATION AND ANGIOGENESIS  
 
RACHEL XI-YEEN HO 
ABSTRACT 
Angiogenesis, the formation of new vessels, is a highly regulated and complex 
cellular process, which plays a crucial role in physiological processes such as 
embryological development and wound healing. Aberrant angiogenesis is a key feature of 
common human pathologies, including cancer and inflammation. Neurogenic locus notch 
homology protein 2 (NOTCH2) signaling is an evolutionarily conserved pathway and a 
major player in regulating angiogenesis. Despite its fundamental involvement in both 
embryonic development and human diseases, the processes through which the NOTCH 
pathway modulates angiogenesis are not fully elucidated.   
We have identified Major Intrinsically disordered NOTCH2-Associated Receptor 
(MINAR) as a novel ligand for NOTCH2. The main objectives of this project were to 
demonstrate the mechanism of association between MINAR with NOTCH2, and its 
biological importance in angiogenesis. Our findings reveal that MINAR is an intrinsically 
disordered cell surface receptor, which is highly expressed in endothelial cells and other 
tissues of human vasculature. The physical association between MINAR and NOTCH2 
increases its order and stability, and also reduces the degradation of MINAR. Moreover, 
we demonstrate that MINAR regulates NOTCH2 activation to inhibit angiogenesis. 
Taken together, the data suggest that MINAR is a novel ligand of NOTCH2 and a key 
regulator of angiogenesis. 
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INTRODUCTION 
Angiogenesis is the development of new vessels from pre-existing vessels 
(Folkman, 1996). Physiological angiogenesis largely occurs during the developmental 
stage in utero, though it continues throughout adulthood during events such as wound 
healing and menstruation (Papetti, 2002). Angiogenesis could occur in two forms: non-
sprouting (intussusceptive) angiogenesis and sprouting angiogenesis (Ribatti et al., 2012). 
Intussusceptive angiogenesis is the splitting of a single vessel by the growth and 
formation of interstitial tissue pillars into the lumen, producing a septum that creates two 
new vessels (Burri et al., 1990; Djonov et al., 2000).  Sprouting angiogenesis is the 
formation of new vessels by branching off from a main vessel. The current model for 
sprouting angiogenesis involves of two main cell types, tip and stalk cells (Kurz et al., 
1996). Tip cells are migratory and distinguished from other endothelial cells as being 
highly polar, possessing long filopodia, and non-proliferating (Gerhardt et al., 2003). In 
contrast, stalk cells are highly proliferating and form tight and adherent junctions to 
support the lumen of the newly sprouting vessel (Dejana et al., 2009; Gerhardt et al., 
2009). 
Angiogenesis is governed by complex cross-talks between pro-angiogenic and 
anti-angiogenic factors that coordinate the dynamic equilibrium of cell migration, cell 
proliferation, and cell survival (Rousseau, 1997; Adams, 2007; Adair, 2010). Although 
various proteins are involved in the regulation of angiogenesis, three main pathways 
involved in the regulation of angiogenesis have been identified and include the vascular 
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endothelial growth factor (VEGF) pathway, Ephrin (Eph) pathway, and NOTCH 
pathway. 
 
Role of VEGF in angiogenesis 
A) VEGF ligands 
VEGF, which was originally identified as Vascular Permeability Factor (VPF), is 
the most prominent player in sprouting angiogenesis (Hoeben et al., 2004). The VEGF 
ligands family consists of seven forms (VEGF A-F and Placental Growth Factor (PlGF)). 
Among all the VEGF ligands, VEGF-A is the best-characterized potent inducer of 
sprouting angiogenesis (Ferrara et al., 2003). Release of VEGF-A in response to 
angiogenic stimuli, such as hypoxia (i.e., low oxygen), is responsible for initiating tip cell 
selection, the first step in sprouting angiogenesis, where VEGF-A triggers differentiation 
in a single endothelial cell by binding to and activating VEGF receptor-2 (VEGFR-2) 
(Gerhardt et al., 2003; Krock et al., 2011). The spatial concentration gradient of VEGF-A 
is critical in providing directional guidance and extension of filopodia in tip cells 
(Ruhrberg et al., 2002; Ferrara et al., 2003). Additionally, VEGF-A stimulates the 
proliferation and induces chemotaxis of stalk cells during the initiation of branching 
angiogenesis up the concentration gradient (Klagsbrun et al., 1999; Dvorak et al., 2007). 
The amalgamation of tip and stalk cell processes creates a snail trail pattern of vascular 
formation as a new vessel is formed from stalk cells following the path of migration by 
the tip cells (Connor et al., 2015). 
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B) VEGF Receptors 
There are three tyrosine kinase VEGFRs, VEGFR-1, VEGFR-2, and VEGFR-3 
(Takahashi, 2011). As single-pass receptor tyrosine kinases, the binding of VEGF ligands 
to immunoglobulin domains on the extracellular region of VEGFR monomers prompts 
dimerization, activation, and trans-phosphorylation of VEGF receptors (von Tiedemann 
et al., 2002). Activation of VEGF signaling stimulates the production of platelet 
activating factor (PAF), increasing mitogenesis and permeability of the vasculature 
(Ogawa et al., 1998; Bernatchez et al., 2002). While VEGFR-1 has high affinity for 
VEGF-A ligand, it possesses weak kinase activity and may function as either a promoter 
or an inhibitor of angiogenesis by acting as a decoy receptor, competing with VEGFR-2 
for VEGF-A binding (Hiratsuka et al., 1998; Meyer et al., 2005; Funahashi et al., 2010). 
VEGFR-2, on the other hand, has highly active kinase activity and is largely responsible 
for regulating cellular responses to VEGF-A (Yancopoulos et al, 2000; Rahimi, 2006).  
 
C) Role of posttranslational modifications in regulation of VEGFRs and 
angiogenesis  
 Recent studies have revealed additional dimensions of regulation on the VEGF 
pathway in the form of posttranslational modification by glycosylation or 
phosphorylation and methylation (Rahimi and Costello, 2015). Extracellular 
glycosylation on the immunoglobulin domains of VEGFR-2 is important for ligand 
dependent activation for signal transduction (Takahashi et al., 1997; Chandler et al., 
2016). On the intercellular region, the mode of modification is phosphorylation, which 
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occurs on tyrosine, serine, and threonine residues. A study done using single tyrosine 
mutations on VEGFR-2 found that phosphorylation of tyrosine Y1052 and Y1057 
residues was required for kinase activity (Meyer et al., 2008). Furthermore, Y1173 
phosphorylation modulates VEGFR-2 activity by recruiting important signaling factors 
such as PLC𝛾1 and p85 of PI3-kinase (Dayanir et al., 2001; Meyer et al., 2003). Another 
method of modulating VEGFR activity is through methylation of lysine (Lys) and 
arginine (Arg) residues (Rahimi and Costello, 2015). Methylation of Lys1041 on 
VEGFR-2 is necessary for regulating VEGFR-2 activation and angiogenesis (Hartsough 
et al., 2013). 
Given the relatively low expression in typical adult tissue and significant 
involvement in tumor angiogenesis, VEGF as well as VEGFRs have been targets for 
treatment of angiogenesis related pathologies using inhibitors such as bevacisnub and 
sunitinib (Elice, et al., 2012). 
 
Role of Ephrin receptors in angiogenesis 
Eph receptor tyrosine kinases belong to the largest class of receptor tyrosine 
kinases, and are implicated in a diverse variety of cellular responses, such as cell 
adhesion, invasion, and repulsion (Poliakov et al., 2004). They also regulate 
vasculogenesis, angiogenesis, and axon pathfinding during embryonic development 
(Egea, 2007). 
Ephs are divided into type A and B based on their association with ligands 
Ephrins A or B (Kullander and Klein, 2002). Both types conform to the typical structure 
	  5 
of receptor tyrosine kinases, which include an extracellular globulin ligand-binding 
domain, a transmembrane domain, and an intracellular kinase domain (Yancopoulos et al, 
2000).  
Similar to Eph receptors, Ephrin ligands are classified into Class A or Class B. 
Class A Ephrins preferentially binds EphA receptors and are anchored to the plasma 
membrane by glycosylphosphatidylinisotol (GPI) while class B ephrins differ in having a 
transmembrane domain and typically associating with EphB receptors (Yancopoulos et 
al, 2000. Despite this preference of receptor-ligand association within each class, there 
exists a high degree of promiscuity between the each class of Ephs and ephrins (Pasquale, 
2004). 
Ephrin/Eph pathway activation is unique among RTKs, which involves the 
formation of ligand clusters or multi-dimerization (Davis et al., 1994; Surawska et al., 
2004). Furthermore, unlike the ‘forward signaling’ mechanism of most RTKs, the 
Eph/ephrin pathway signaling is bi-directional, meaning both Eph receptors and ephrin 
ligands are capable of generating cellular responses (Himanen and Nikolov, 2003). 
Cellular responses elicited by Ephrin/ephs, such as cell motility and adherence, 
are key components in regulating angiogenesis, particularly in arterial and venous vessel 
formation. Of particular interest are ephrinB2 ligand and receptor EphB4, which are 
largely expressed in arterial endothelial cells and venous endothelium, respectively 
(Lawson, 2002; Kujiper et al., 2007). EphrinB2 and EphB4 are responsible for 
artery/venous differentiation early in development and are crucial in establishing 
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endothelial cell positioning for sprouting capillary growth during vessel remodeling 
(Wang et al., 1998).  
 
Role of NOTCH pathway in angiogenesis 
The NOTCH signaling pathway represents another fundamental regulator of 
angiogenesis. First identified in drosophila, the NOTCH signaling is a highly conserved 
pathway and central in cell differentiation and cell fate determination (Artavanis-
Tsakonas et al., 1999; Greenwald et al., 1983). Knockout mice studies of the NOTCH 
signaling pathway have demonstrated that embryos lacking these receptors were 
incompatible with life, highlighting the importance of NOTCH expression during 
embryological development (Swiatek et al., 1994). Mammals possess four distinct 
NOTCH receptors, NOTCH1, NOTCH2, NOTCH3, and NOTCH4 (Radtke, 2003). 
NOTCH receptors are single-pass transmembrane proteins that differ in the number of 
EGF repeats on the extracellular domain and the presence of Transcription Activation 
Domains (TAD) and proline, glutamate, serine, and threonine (PEST) motifs within the 
intracellular domain (Radtke, 2003; Chillakuri et al., 2012; Olsauskas-Kuprys et al., 
2013).  
In mammals, NOTCH activation is initiated by 5 single pass transmembrane 
ligands, serrate-like ligands, known as Jagged, (JAG 1 and 2) and Delta-like ligands (Dll 
1, 3, and 4) (Radtke, 2003). These ligands are noted for containing an N-terminal DSL 
(Delta, Serrate, Lag2) domain that contains a binding site for NOTCH (Tax et al., 1994; 
Chillakuri et al,. 2012).   
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A) Canonical NOTCH Signal Transduction  
 NOTCH ligands interact with the NOTCH receptors in trans between cells, 
leading to a sequence of cleavages culminating in a S3 proteolytic cleavage of the 
NOTCH intercellular domain (NICD) by gamma secretase (GS) and its release into the 
cytoplasm (Kopan and Ilagan, 2009). NICD is subsequently translocated into the nucleus 
where it associates with transcription factors and DNA binding proteins such as 
recombining binding protein suppressor of hairless (RBPJ or CBF-1) and Mastermind 
(MAML1), forming a transcriptional complex that activates target genes, such as 
HES/HRT (Hairy/Enhancer of Split genes) (Greenwald, 1998).  
 Ligands are also capable of inhibiting NOTCH signaling through autonomous cis-
interactions between ligands and NOTCH on the same cell, though the mechanism of 
such interaction is not fully understood (Sakamoto et al., 2002; Ladi et al., 2005). 
 
B) Role of NOTCH signaling in angiogenesis 
The involvement of NOTCH signaling in angiogenesis is strongly supported by 
expression of NOTCH receptors and ligands in endothelial cells, particularly Dll4 
expression, which is restricted to arterial endothelium (Shutter et al., 2000). Up-
regulation of ligand Dll4 in response to VEGF signaling activates NOTCH pathway, 
inhibiting tip cell selection, endothelial cell migration, and angiogenesis (Suchting et al., 
2007; Trinidade et al., 2008). Conversely, JAG 1 antagonizes the effects of Dll4/NOTCH 
signaling. Up-regulating JAG 1 increases sprouting angiogenesis and stability of capillary 
vessels (Benedito et al., 2009). 
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As with most biological processes, angiogenesis is a complex event regulated by 
the coordination between the multiple signaling pathways. Accordingly, NOTCH 
modulates angiogenesis through regulating VEGFR2 and Ephrin pathways (Liu et al., 
2003; Lobov et al., 2007). Like VEGF, NOTCH signaling is also involved the tip cell 
determination. VEGF-A/VEGFR-2 signaling within a single endothelial cell increases its 
production of ligand Dll4, which interacts with NOTCH1 receptors on neighboring cells, 
causing a reduction in VEGFR-2 expression while simultaneously increasing VEGFR-1 
expression (Jakobsson et al., 2010). By altering the ratios of VEGFR expression, NOTCH 
signaling decreases VEGF-A sensitivity among other endothelial cells , allowing just one 
endothelial cell with an up-regulation of VEGFR-2 and Dll4, and high sensitivity to 
VEGF-A to become a tip cell. 
NOTCH also mediates vascular morphogenesis by regulating the expression of 
EphB4 and ephrin B2 (Heroult et al., 2006). Stimulation of NOTCH signaling by 
overexpressing Dll4 promotes arteriogenesis during vascular development in endothelial 
cells by up-regulating ephrin B2 (Duarte et al., 2004; Kofler et al., 2011) while 
simultaneously depressing expression of venous marker EphB4 (Trinidade et al., 2008). 
Animal studies using zebrafish models have shown NOTCH pathway to exert 
negative regulation on capillary branching, making NOTCH regulation a potentially 
reliable target of treatment for cancers that are non-responsive to anti-VEGF treatments 
(Siekmann and Lawson, 2007; Suchting et al., 2007).s 
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C) The role of NOTCH in cancer development 
A study published by Ellisen et al. (1991) was the first to reveal the involvement 
of NOTCH pathway with cancer in human T-ALL lymphoma. Now, it is well accepted 
that aberrant NOTCH signaling is involved in the regulation of key tumorigenic 
processes such as proliferation, epithelial to mesenchymal transition (EMT), and 
angiogenesis (Timmerman et al, 2004; Ridgeway et al., 2006). Paradoxically, it appears 
that NOTCH may act as both a promoter and tumor suppression even within the same 
tumor (Radtke, 2003; Leong et al., 2006).  
Canonical Dll4/NOTCH signaling is commonly manipulated during the course of 
tumor development (Mailhos et al., 2001). Tumors heavily rely on vasculature as a 
resource for tumor expansion and network for metastasis (Cavallo et al., 1972; Folkman 
and Hanahan, 1991). During initial tumor growth, the release of tumor angiogenesis 
factors (TAF) from tumors and the creation of a hypoxic and nutrient-deprived 
environment stimulate persistent activation of VEGF and NOTCH pathways (Folkman et 
al., 1971; Ferrara, 2002; Kofler et al., 2011). This induces over-abundant vessel 
formation that is essential for tumor progression. 
Studies into Dll4/NOTCH regulation of tumor angiogenesis discovered that 
blocking Dll4 interaction with NOTCH-2 with DLL-4 specific antibodies cause hyper-
proliferation of endothelial cells that resulted in defective vasculature, affecting blood 
flow and thus inhibiting tumor growth (Ridgway et al., 2006).  
 
	  10 
Pathological Angiogenesis 
Pathological angiogenesis is the dysregulation of angiogenic processes that is 
exemplified by deficient or excessive vessel formation. An overstimulation of 
angiogenesis is associated with human pathologies, including tumorigenesis and 
metastasis (Klagsbrun, 1991).  
Tumor growth and angiogenesis are inter-dependent events that modulate each 
other (Warren and Shubik et al., 1966; Folkman, 1971). Studies conducted on 
tumorigenesis demonstrated that, not only are tumors able to recruit and induce 
proliferation of endothelial cells and vessel sprouting to the site of growth, solid tumors 
rely significantly on an established blood source to evolve past dormancy to a metastatic 
state (Cavallo et al., 1972; Greene, 1941; Holmgren et al., 1995). This critical 
relationship between angiogenesis and tumorigenesis has made anti-angiogenesis an 
exciting and, more importantly, specific area of study for therapeutics targeting tumor 
growth and metastasis (Kubota, 2012). 
 
Identification of Major Intrinsically Notch-2 Associated Receptor (MINAR) as a 
novel regulator of angiogenesis  
 The purpose of this study was to elucidate the role of MINAR in angiogenesis. 
Originally named KIAA1024, Major Intrinsically-disordered Notch-2 Associated 
Receptor (MINAR) was first identified as one of 2031 novel cDNAs of the Human 
Unidentified Gene-Encoding (HUGE) protein database in an effort to characterize these 
proteins (Kikuno et al., 2004). Subsequently, MINAR was identified in our lab alongside 
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several other novel immunoglobulin containing cell surface proteins such as 
Immunoglobulin Proline-rich Receptor-1 (IGPR-1), TMIGD1, and Immunoglobulin 
Cysteine-rich Receptor-1 (IGCR-1) (Rahimi et al., 2012; Arafa et al., 2016; Wang et al., 
2016). Found on human chromosome 15, this protein is composed of 916 amino acids 
and has a predicted molecular weight is 100kDa. MINAR was determined to be an 
intrinsically disordered novel cell surface receptor and a putative ligand for the NOTCH-
2 receptor. MINAR was postulated to negatively regulate angiogenesis via the canonical 
NOTCH signaling pathway through direct association with NOTCH 2 receptor.  
The specific goals of this project were as follows:  
A) Test the hypothesis that MINAR is an intrinsically disordered protein. 
B) Establish the role of MINAR in regulation of NOTCH-2 activity. 
C) Elucidate the regulatory role of MINAR on NOTCH-2 mediated angiogenesis. 
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METHODS  
 
Antibodies and Reagents 
 Rabbit polyclonal anti-MINAR antibody was developed in our laboratory and its 
specificity was further validated (unpublished data). Anti-MINAR antibody was used in 
1:2,000 dilutions to detect for the presence of MINAR in PAE and HEK-293 cells in 
western blot analysis. Mouse monoclonal anti-GAPDH antibody (1:5000 dilution) and 
mouse polyclonal anti-alpha tubulin antibody (1:5000 dilution) were purchased from 
Santa-Cruz Biotechnology, Inc. Rabbit polyclonal anti-NOTCH2 antibody was purchased 
from Cell Signaling Technology. 
 
Cell Culture 
Human Embryonic Kidney cells (HEK-293) and Porcine Aortic Endothelial cells 
(PAE) were maintained in Dulbecco’s Modified Eagle’s Media (DMEM) containing 10% 
fetal bovine serum (FBS) and 50 units/mL Penicillin and Streptomycin. Cells were 
incubated at 37℃ in a 5% CO!  humidified chamber. 
 
Cell Transfection  
HEK 293 cells were plated at 60% confluence at the time of transfection and 
media was aspirated and replaced with 2mL serum free DMEM.  In an epi-tube, 3ug of 
MINAR shRNA control, 412, 615, or 719 plasmids or control shRNA, 9uL PEI 
(polyethylenimine), and 400uL serum free DMEM were incubated in the tissue culture 
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hood for 15 minutes before being added to the cells. Cells were then incubated for 6 
hours before 2mL of DMEM 10% FBS was added to existing media.  
After 24 hours, media in the plates were replaced with DMEM 10% FBS with 
puromycin to select for transfected cells. Some cells were lysed after 48 hours to check 
for the knock down of MINAR. 
  
Retroviral virus production 
 HEK-293 GPG cells were grown to 90% confluence in GPG Growth Media 
before being transfected with shRNA MINAR using pGIPZ. After 24 hours, media was 
changed to Viral Producing Media and the virus was collected at 72, 96, 120, and 144 
hours as described (Rahimi, et al., 2000, JBC). 4ml of virus was added to HEK-293 cells 
at 70% confluence on a 60mm plate along with 4ul of polybrene and left for 16-20 hours. 
DMEM 10% FBS with puromycin is added the next day to select for transduced cells. 
 
Western Blot Analysis 
 Cells were rinsed twice with H/S (25mM Hepes (pH 7.4)/150mM NaCl) and 
collected in lyse buffer (10mM Tris-HCl, 10% Glycerol, 5 mM EDTA (pH 7.4), 50 mM 
NaCl, 50 mM NaF, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 20 
mg/ml aprotinin). The resulting solution was centrifuged and supernatant was collected. 
5X Sample Buffer (3.8% Tris-base, 50% glycerol, 5% sodium dodecyl sulphate (SDS), 
5% β-mercaptoethanol, 0.0025% bromophenol blue) was added to whole cell lysates 
before being placed on heat block at 95℃ for 5 minutes. Cell lysate samples were 
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resolved on 10 % SDS-polyacrylamide gel electrophoresis (SDS-PAGE) then transferred 
onto polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with blotto 
(2% non-fat dry milk and 0.05% Tween-20 in Western Rinse) for 1 hour on a rocker. 
After washing with western rinse for 5 minutes, membranes were incubated with primary 
antibody for 1 hour at room temperature. Following three 10 minutes washes in western 
rinse, membranes were incubated with secondary antibodies for 1 hour. The membranes 
were washed again in western rinse three times, 10 minutes each.  
 
4PBA Cell Culture Treatment and Trypsin digest 
 HEK-293 cells were incubated with 10mM PBA for 2 hours before being lysed. 
Cells designated for trypsin digest were lysed by mechanical homogenization using 
sonication with Thermo-Fisher Sonicator Dismembrator Model 1000. 20ng of trypsin 
was added to 50ul of whole cell lysate and was allowed to digest at room temperature for 
0, 30, and 60 minutes. Following this, 5X sample buffer was added to lysates (1:5 
dilution) and samples were denatured in the heat block at 95℃ for 5 minutes. Cell lysates 
were resolved on 10% SDS-PAGE and analyzed by Western Blot using anti-MINAR 
antibody. 
 
Matrigel Capillary Formation Assay 
 The surface of each well in a 24 well plate was coated with 200 µL of Matrigel. 
PAE cells expressing pMSCV empty vector and MINAR (2  ×  10! cells per well, 
triplicate wells per group) are seeded in each well and allowed to adhere for 1 hour. Each 
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cell line is then subjected to treatment with 500ul of GSI (purchased from Calbiochem). 
After 24 hours, images of the cell are captured using Zeiss microscope camera and 
Lumenera INFINITY ANALYZE Software. Formation of capillary tubes was analyzed 
with the Angiogenesis Analyzer via ImageJ software. 
 
Reverse Transcription Quantitative Polymerase Chain Reaction Analysis of MINAR 
 TRIzol reagent (Life Technologies, Carlsbad, CA) was used to isolate total RNA. 
One microgram of total RNA from at least three mice per group was subjected to reverse 
transcription using High Capacity cDNA Reverse Transcription Kit (Life Technologies) 
according to manufacturer protocol. RT-qPCR was performed according to manufacturer 
recommendations (Applied Biosystems) and 18S housekeeping gene was used as internal 
controls.	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RESULTS 
 
MINAR is an intrinsically disordered protein  
Our initial in silico analysis predicted MINAR as a putative cell surface protein 
with a single-pass transmembrane and a short cytoplasmic domain. The N-terminus 
extracellular domain of MINAR represents the largest portion of MINAR.  Further 
examination using Metadisorder, an online program comprising 13 different protein 
disorder programs like DisEMBL, DISOPRED2, DISpro, Globplot, iPDA, IUPred, 
Pdisorder, Poodle-l, PrDOS, and Spritz, consistently predicted approximately 70% of 
MINAR is intrinsically disordered (Fig. 1) (unpublished data, Nader Rahimi, 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. MINAR is predicted as intrinsically disordered. Metadisorder analysis 
predicted 70% of the MINAR sequence to be disordered. A disorder probability above 
0.5 is considered disordered. 
 
Considering the predicted intrinsically disordered nature of MINAR, we decided 
to explore its disordered characteristics experimentally. Accordingly, we hypothesized 
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that treatment of HEK-293 cells with 4-phenylbutyrate (4PBA), a well-characterized 
chemical chaperone should stabilize MINAR and increase its expression.  On top of 
relieving protein aggregations, 4PBA is also known to reduce degradation of misfolded 
proteins by imparting stability to these proteins (de Almeida, 2007).  Our preliminary 
Western Blot analysis showed that treatment of HEK-293 cells with 4PBA demonstrates 
increased expression of MINAR (Fig. 2a).  Quantification of western blot revealed 
approximately a third more MINAR expression in 4PBA compared to untreated cells 
(Fig. 2b). The data suggests the idea of MINAR as an intrinsically disordered protein; 
however further studies are required to establish MINAR as an intrinsically disordered 
protein.  
 
 
 
 
 
 
 
Figure 2.  4PBA increases expression of MINAR in HEK293 cells. A) HEK293 cells 
expressing endogenous levels of MINAR were treated with 10mM of 4PBA for 2 hours 
before being lysed. Whole cell lysates were blotted for MINAR. GAPDH was used as 
loading control. B) ImageJ quantification of MINAR expression between 4PBA treated 
and untreated groups from western blot analysis. Graph represents a single western blot. 
 
Next, we examined whether the increased expression of MINAR in response to 
4PBA treatment is associated with its increase stability and folding. We hypothesized that 
	  
	  18 
if 4PBA treatment indeed improves MINAR folding and stability, the 4PBA treatment 
should decrease the susceptibility of MINAR to partial trypsin digest.    
To this end, HEK-293 cells with and without 4PBA treatment were partially 
digested with 20ng of trypsin at room temperature for 0, 15, and 30 minutes. Western blot 
analysis showed that 4PBA treated cells was more resistant to the trypsin treatment, 
indicating that 4PBA treatment increased the folding of MINAR (Fig. 3a). The amount of 
MINAR detected over the time subjected with trypsin digest was quantified and 
normalized. The resulting graph depicted a decrease in rate of degradation from HEK293 
cells treated with 4PBA (Fig. 3b). Taken together, the data suggests that the 4PBA 
treatment increases the folding of MINAR leading to the stabilization of its secondary 
structure, which reduces MINAR’s susceptibility to degradation.    
Figure 3. 4PBA reduces the rate of degradation of MINAR by trypsin. A) Untreated 
HEK293 cells and cells treated with 4PBA were partially digested by 20ng of trypsin for 
0, 15, and 30 minutes before being blotted with anti-MINAR. GAPDH was used as 
loading control. B) ImageJ quantification of MINAR bands was plotted and normalized 
using MINAR/GAPDH. 
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Identification of NOTCH2 as MINAR binding protein  
Given its large and disordered characteristics, we hypothesized that similar to 
other known intrinsically disordered proteins such as tumor suppressor p53, MINAR may 
interact with other proteins in order to gain structure and stability (Iakoucheva, 2002). 
We used liquid chromatography–tandem mass spectrometry (LC-MS/MS) to identify 
putative MINAR associated proteins. LC-MS/MS analysis identified NOTCH2 as a 
possible MINAR interacting protein (unpublished data, Kevin Chandler and Nader 
Rahimi, 2015) (Fig. 4).  
 
 
 
 
 
 
 
 
Figure 4. NOTCH2 is a putative binding target of MINAR. Mass spectrum analysis 
illustrates peptide sequence of human NOTCH2. 
 
 
To validate the LC-MS/MS analysis findings, we performed a co-
immunoprecipitation experiment, where MINAR was isolated from HUVEC (human 
umbilical vein endothelial cells) whole cell lysate through immunoprecipitation using 
anti-MINAR antibody and subjected to western blot analysis using anti-NOTCH2 
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antibody. The results illustrated that NOTCH2 was co-immunoprecipitated (co-ip) with 
MINAR (Fig. 5a). As a further proof of concept, the co-ip experiment was repeated with 
the inclusion of MINAR knock down HUVEC cell line. As seen in Fig.5b, western blot 
shows a weak band in lane 2 for NOTCH2 coinciding with the knock down of MINAR 
expression. This indicates a decrease in the amount of NOTCH2 co-immunoprecipitated 
with MINAR in the knock down cell line (unpublished data, Rosana Meyer, 2015). 
 
 
 
 
 
 
 
 
 
 
Figure 5. NOTCH2 is co-immunoprecipitated with MINAR. A) MINAR was 
immunoprecipitated from HUVEC whole cell lysate by anti-MINAR. The resulting lysate 
was run on western blot and blotted with NOTCH2 antibody. Alpha tubulin was used as 
loading control. B) MINAR was purified from shRNA knock down HUVEC whole cell 
lysate with MINAR antibody and run along side an shRNA control. Western blot was 
blotted with NOTCH2 and MINAR antibody. Alpha tubulin was used as loading control. 
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MINAR co-localizes with NOTCH2 
In order to further examine the relationship between MINAR and NOTCH2, we 
studied whether MINAR co-localizes with NOTCH2 in cells. PAE cells were subjected 
to immunofluorescence microscopy to visualize the co-localization of MINAR with 
NOTCH2. The analysis demonstrated that MINAR and NOTCH2 are co-localized 
together at the cell surface of PAE cells (Fig. 6). Altogether, these experiments suggest 
that MINAR physically interacts with the NOTCH2. 
 
 
 
 
 
 
 
 
Figure 6. MINAR and NOTCH-2 co-localize at the cell surface. A) 
Immunofluorescence microscopy imaging of PAE cells depict MINAR at the cell surface. 
B) Immunofluorescence microscopy imaging of PAE cells depict NOTCH2 at the cell 
surface. C) Superimposition of A and B illustrate NOTCH2 and MINAR co-localized at 
the cell borders (unpublished data, Rosana Meyer and Nader Rahimi 2015). 
 
MINAR is expressed in human blood vessels  
To determine expression of MINAR in human tissues, we carried out qPCR and 
Western Blot analyses. Our analysis revealed the highest level of MINAR in the aorta, 
brain, and bone marrow (Fig. 7a). Subsequently, we performed immunohistochemistry 
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staining to determine which cell types MINAR is expressed in. MINAR was found 
specifically expressed in endothelial, aortic smooth muscle, and cytoskeletal muscle cells 
(Fig. 7b) (unpublished data, Rosana Meyer 2015). Taken together, the data demonstrate 
that MINAR is expressed in endothelial cells and associates with NOTCH2.  
 
Figure 7. MINAR is expressed in human organs and tissues. A) qPCR analysis for 
relative expression of MINAR in human tissue is highest in the aorta, bone marrow, and 
brain. B) Immunohistochemical assay of human tissue suing anti-MINAR stains 
specifically for MINAR in endothelial, smooth, and cytoskeletal muscle cells.  
 
MINAR interaction with NOTCH-2 potentially stimulates NOTCH2 activation  
Experiments described above demonstrated that MINAR physically associates 
with NOTCH2. Therefore, we hypothesized that MINAR acts as a putative ligand to 
regulate NOTCH2 activation. To test our hypothesis, we knocked down MINAR with 
three different shRNAs and examined NOTCH2 activation. Expression of full length 
NOTCH 2 (200kD) and NICD (120kD), which corresponds to active NOTCH2 were 
compared between knockdown and endogenous MINAR groups. Western blot analysis 
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depicts HEK293 silenced for MINAR with a relatively darker band at 200kD and a 
lighter band at 120kD compared with shRNA control lysates, which had a relatively 
lighter band at 200kD and a stronger band lower down at 120kD. This subtle difference 
provides preliminary data that suggests diminished MINAR expression may correspond 
with a slight decrease in NOTCH2 activity. Additional rounds of shRNA MINAR knock 
down are required to optimize detection of the apparent affect of MINAR on NOTCH2 
activity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. MINAR activates NOTCH2. A) Western Blot analysis of HEK293 
knockdown MINAR cell lines and control shRNA were blotted for NOTCH2 and 
MINAR. Alpha tubulin was used as loading control. B) ImageJ quantification of 
NOTCH2 activation from western blot. Graph represents a single western blot. 
 
MINAR inhibits angiogenesis  
NOTCH activation is known to inhibit angiogenesis (Siekmann and Lawson, 
2007). Accordingly, we hypothesized that MINAR interaction with NOTCH2 and 
subsequent NOTCH2 activation could inhibit angiogenesis. To explore the involvement 
of MINAR in angiogenesis, we studied capillary tube formation of PAE cells expressing 
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MINAR. The capillary tube formation of cells were observed under Zeiss microscope and 
images were captured using INFINITY ANALYZE software. The data showed that after 
24 hours, capillary tube formation in the MINAR/PAE group was significantly decreased 
and were less extensive than the empty vector, or EV/PAE, control group (Fig. 8a-b). 
Additionally, capillaries formed in MINAR/PAE cells had more disruptions and showed 
signs of capillary retraction.  
To provide further evidence that regulation of angiogenesis by MINAR is 
mediated through the NOTCH-2 pathway, we inhibited NOTCH-2 signaling by treating 
PAE cells with gamma secretase inhibitor (GSI) and NOTCH-2 blocking antibodies. GSI 
inhibits the S3 cleavage of NOTCH receptors and prevents the release the NICD while 
NOTCH-2 B9 antibody is expected to physically prevent MINAR/NOTCH-2 association 
(Olsauskas-Kuprys, 2003; Paris et al., 2005). Both MINAR/PAE cell groups treated with 
GSI and NOTCH-2 B9 antibodies demonstrated significantly more capillary branching 
than the control group, appearing to counter the inhibitory effect that MINAR exerts on 
angiogenesis (Fig. 8d). Interestingly, cells treated with NOTCH-2 B9 antibodies 
exhibited approximately twice as much capillary tubular length formation than cells with 
the GSI treatment (Fig. 8d). Taken together, the results indicate NOTCH-2 signaling is 
involved in the inhibition of capillary formation induced by MINAR.  
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Figure 9. MINAR inhibits capillary tube formation. A) EV/PAE cells were grown on 
Matrigel and treated with GSI (500uL) and NOTCH2 blocking antibody (1ml). Images 
were captured after 24 hours. B) MINAR/PAE cells were grown in Matrigel and treated 
with GSI (500uL) and NOTCH2 blocking antibody (1ml). Images were captured after 24 
hours. C) ImageJ quantification of total tubular length from EV/PAE cells using 
Angiogenesis analyzer. D) ImageJ quantification of total tubular length from 
MINAR/PAE cells using Angiogenesis analyzer. 
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DISCUSSION 
 
 In this study, we demonstrate that MINAR is a novel intrinsically disordered 
protein that interacts with NOTCH-2.  
We used Metadisorder protein disorder program to analyze the intrinsically 
disordered nature of MINAR. MINAR was predicted to be a highly intrinsically 
disordered protein, with 70% of MINAR appearing to have no structure. The ordination 
of MINAR as an intrinsically disordered protein alludes to its key biochemical and 
possible biological function. For instance, a critical aspect behind the functionality of 
most intrinsically disordered proteins (IDP) is the dependence on other proteins to gain 
stability and order (Atkinson et al., 2016). While their lack of structure make IDPs 
flexible and accessible, the high degree of disorder means IDPs usually have a short half-
life as they often form aggregations and are recognized by 20S proteasomes, resulting in 
degradation ‘by default’ (Tompa et al., 2008, Asher et al., 2006; Uversky; 2010).  In this 
regard, MINAR is not expected to have a long half-life, unless it interacted with 
NOTCH2 or with other yet unknown proteins.  
Considering IDPs gain some stability from forming secondary structures upon 
association with other proteins, we sought to elucidate the significance of structural 
stability on MINAR. Treating HEK293 cells with chemical chaperone 4PBA encouraged 
folding in MINAR, which concealed recognition sites and thus improved the stability of 
MINAR. This gain of order not only accounts for the increased expression, but also 
reduced susceptibility of MINAR to degradation upon trypsin digestion. Results from 
mass spectrometry, in vivo co-localization study, and co-immunoprecipitation assays all 
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revealed a physical interaction between NOTCH-2 and MINAR. Taken together, these 
observations underscore the critical role of NOTCH2 in governing the expression and 
possible function of MINAR. In this regard, NOTCH2 acts to safeguard MINAR from 
degradation, which represents an intriguing characteristic of MINAR.  
Another important aspect of this study is the demonstration that MINAR is 
expressed in human blood vessels and endothelial cells, raising a possibility that MINAR 
could play a role in angiogenesis and other endothelial functions. Our studies revealed 
that MINAR plays a critical role in angiogenesis by modulating capillary tube formation 
of endothelial cells. Over-expression of MINAR inhibited capillary tube formation in 
PAE cells. Intriguingly, the observed effect of MINAR in capillary tube formation of 
endothelial cells is similar to that of NOTCH pathway, which is congruent with our 
hypothesis that MINAR activation of NOTCH2 would inhibit angiogenesis. In support of 
possible MINAR/NOTCH2 axis in the regulation of angiogenesis, preventing the release 
of the NOTCH Intracellular Domain (NICD) with either GSI or NOTCH-2 B9 antibody 
impeded normal anti-angiogenic effect of MINAR. This observation further signifies that 
MINAR plays a role in inhibiting angiogenesis and that the NOTCH-2 signaling pathway 
mediates the anti-angiogenesis effects observed. 
 The involvement of MINAR in regulating NOTCH2 activation and angiogenesis 
pegs it as a potential site of anti-angiogenesis or anti-cancer therapy. Targeting 
pathologic angiogenesis, either insufficient (e.g. ischemic cardiovascular diseases) or 
excessive angiogenesis (e.g. cancer & others) is a promising strategy that could 
revolutionize treatment of human diseases ranging from peripheral artery disease to 
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diabetic retinopathy and cancer. Current strategies mainly targets vascular endothelial 
growth factor (VEGF) pathway. Although they confer clinical benefits, their successes 
are restricted by insufficient efficacy, refractory or development of resistance (Ferrara 
and Kerbel, 2005; Fukumura and Jain, 2012). Cardiovascular disease is the leading cause 
of death in US and is associated with occlusion of the blood vessel in the affected organs. 
Restoring blood supply through therapeutic angiogenesis, in effect stimulating the growth 
of new blood vessels, is a tantalizing strategy that could lead to the successful treatment 
of cardiovascular diseases (Deveza et al., 2012). Thus, comprehensive insight into the 
regulation of vascular growth for the resolution of a particular pathology can bring 
indisputable therapeutic value to a diverse range of human pathologies. Similarly, the 
application of tissue engineering for organ regeneration and wound healing requires a 
more extensive understanding of vessel stabilization and growth. 
Considering the clinical importance and therapeutic potential of modulating 
vascular network in various diseases, further investigation into the functional importance 
of MINAR and mechanism of its action in normal and pathological circumstances, could 
grant further insights into the mechanisms of angiogenesis and possible novel 
therapeutics.   
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